Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 12, 2014, Pages 2065-2069

  Gangadharan, B ^a,b   Delignat, S ^a,b   Ollivier, V ^a   Gupta, N ^a,b   Mackman, N ^c   Kaveri, S V ^a,b   Lacroix Desmazes, S ^a,b  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Blood coagulation; Coagulation factor VIII; Hemophilia A; Humoral immune response; Thrombin; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; FACTOR VIII V634M; HIRUDIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1H1; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; RECOMBINANT PROTEIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CROSS REACTION; GENE MUTATION; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; MUTANT; NONHUMAN; PARALLEL DESIGN; PROTEIN EXPRESSION; PROTHROMBIN TIME; TREATMENT RESPONSE; WILD TYPE; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMISTRY; DISEASE MODEL; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; INFLAMMATION; MUTATION; PLASMID; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODIES, NEUTRALIZING; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FACTOR VIII; HEMOPHILIA A; IMMUNITY, HUMORAL; INFLAMMATION; MICE; MUTATION; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THROMBIN; THROMBOPLASTIN; WARFARIN;

EID: 84916631994     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12740     Document Type: Article

References (16)

1. Whelan SF, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, Male C, Windyga J, Tiede A, Schwarz HP, Scheiflinger F, Reipert BM. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039-48.
2. Schwartz RH. T cell anergy. Sci Am 1993; 269: 62-3.
3. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26-34.
4. Skupsky J, Zhang AH, Su Y, Scott DW. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood 2009; 114: 4741-8.
5. Meeks SL, Cox CL, Healey JF, Parker ET, Doshi BS, Gangadharan B, Barrow RT, Lollar P. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 2012; 120: 2512-20.
6. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002; 277: 38345-9.
7. Kirchhofer D, Moran P, Bullens S, Peale F, Bunting S. A monoclonal antibody that inhibits mouse tissue factor function. J Thromb Haemost 2005; 3: 1098-9.
8. Nagai M, Yilmaz CE, Kirchhofer D, Esmon CT, Mackman N, Granger DN. Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis. Neurosurgery 2010; 66: 560-5.
9. Pawlinski R, Wang JG, Owens AP 3rd, Williams J, Antoniak S, Tencati M, Luther T, Rowley JW, Low EN, Weyrich AS, Mackman N. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood 2010; 116: 806-14.
10. Meslier Y, Andre S, Dimitrov JD, Delignat S, Bayry J, Kaveri SV, Lacroix-Desmazes S. Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells. J Thromb Haemost 2011; 9: 719-28.
11. Strukova S. Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis. Front Biosci 2006; 11: 59-80.
12. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
13. Darbousset R, Thomas GM, Mezouar S, Frere C, Bonier R, Mackman N, Renne T, Dignat-George F, Dubois C, Panicot-Dubois L. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012; 120: 2133-43.
14. McGinniss MJ, Kazazian HH Jr, Hoyer LW, Bi L, Inaba H, Antonarakis SE. Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A. Genomics 1993; 15: 392-8.
15. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35: 723-34.
16. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.